Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
COSTS AND EXPENSES:    
Research and development $ 36,157 $ 18,192
General and administrative 14,354 10,636
Total costs and expenses 50,511 28,828
Operating Loss (50,511) (28,828)
Interest income, net 48 210
Net loss (50,463) (28,618)
Warrant deemed dividend (451)  
Preferred stock deemed dividend (1,260) (2,474)
Net loss available to common stockholders $ (52,174) $ (31,092)
Net loss per common share, basic and diluted (in dollars per share) $ (0.55) $ (19.33)
Weighted average common shares outstanding, basic and diluted (in shares) 94,591,715 1,608,568